PUBLISHER: TechNavio | PRODUCT CODE: 1915518
PUBLISHER: TechNavio | PRODUCT CODE: 1915518
Global Human Chorionic Gonadotropin (HCG) Market 2025-2029
The global human chorionic gonadotropin (hcg) market is forecasted to grow by USD 208.6 mn during 2024-2029, accelerating at a CAGR of 4.6% during the forecast period. The report on the global human chorionic gonadotropin (hcg) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global prevalence of infertility and expanding utilization of art, technological advancements and product innovation in biopharmaceutical production, expanding therapeutic applications and growing off-label usage.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2029 |
| Series Year | 2025-2029 |
| Growth Momentum | Accelerate |
| YOY 2025 | 4.3% |
| CAGR | 4.6% |
| Incremental Value | $208.6 mn |
Technavio's global human chorionic gonadotropin (hcg) market is segmented as below:
By Technology
- Natural source extraction
- Recombinant technology
By End-User
- Clinics
- Hospitals
- Diagnostic laboratories
By Route Of Administration
- Injectable
- Oral
- Nasal spray
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the emerging trend of delayed pregnancies among women coupled with expanding art centers as one of the prime reasons driving the global human chorionic gonadotropin (hcg) market growth during the next few years. Also, strategic product approvals and intensifying pharmaceutical sector engagement and growing disposable income and healthcare expenditure in emerging economies will lead to sizable demand in the market.
The report on the global human chorionic gonadotropin (hcg) market covers the following areas:
- Global human chorionic gonadotropin (hcg) market sizing
- Global human chorionic gonadotropin (hcg) market forecast
- Global human chorionic gonadotropin (hcg) market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global human chorionic gonadotropin (hcg) market vendors that include Abbott Laboratories, Cipla Inc., Corona Remedies Pvt. Ltd., Emcure Pharmaceuticals Ltd., Ferring BV, Fresenius Kabi AG, Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Lee BioSolutions Inc, Lijun Pharmaceutical Group Co., Ltd., Lupin Ltd., Merck and Co. Inc., Ningbo Renjian Pharmaceutical Group Co., Ltd, Organon and Co., Sanzyme Pvt. Ltd., Scripps Laboratories Inc., Serum Institute of India Ltd., Sun Pharmaceutical Industries Ltd., The Cigna Group, Zydus Lifesciences Ltd.. Also, the global human chorionic gonadotropin (hcg) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Technology
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
5 Historic Market Size
- 5.1 Global Human Chorionic Gonadotropin (HCG) Market 2019 - 2023
- Historic Market Size - Data Table on Global Human Chorionic Gonadotropin (HCG) Market 2019 - 2023 ($ million)
- 5.2 Technology segment analysis 2019 - 2023
- Historic Market Size - Technology Segment 2019 - 2023 ($ million)
- 5.3 End-user segment analysis 2019 - 2023
- Historic Market Size - End-user Segment 2019 - 2023 ($ million)
- 5.4 Route of Administration segment analysis 2019 - 2023
- Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ million)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
- 6.1 The Impact of AI on the Global Human Chorionic Gonadotropin (HCG) Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
8 Market Segmentation by Technology
- 8.1 Market segments
- 8.2 Comparison by Technology
- 8.3 Natural source extraction - Market size and forecast 2024-2029
- 8.4 Recombinant technology - Market size and forecast 2024-2029
- 8.5 Market opportunity by Technology
- Market opportunity by Technology ($ million)
9 Market Segmentation by End-user
- 9.1 Market segments
- 9.2 Comparison by End-user
- 9.3 Clinics - Market size and forecast 2024-2029
- 9.4 Hospitals - Market size and forecast 2024-2029
- 9.5 Diagnostic laboratories - Market size and forecast 2024-2029
- 9.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)
10 Market Segmentation by Route of Administration
- 10.1 Market segments
- 10.2 Comparison by Route of Administration
- 10.3 Injectable - Market size and forecast 2024-2029
- 10.4 Oral - Market size and forecast 2024-2029
- 10.5 Nasal spray - Market size and forecast 2024-2029
- 10.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- 12.3.1 US - Market size and forecast 2024-2029
- 12.3.2 Canada - Market size and forecast 2024-2029
- 12.3.3 Mexico - Market size and forecast 2024-2029
- 12.4 Europe - Market size and forecast 2024-2029
- 12.4.1 Germany - Market size and forecast 2024-2029
- 12.4.2 UK - Market size and forecast 2024-2029
- 12.4.3 France - Market size and forecast 2024-2029
- 12.4.4 Italy - Market size and forecast 2024-2029
- 12.4.5 Spain - Market size and forecast 2024-2029
- 12.4.6 The Netherlands - Market size and forecast 2024-2029
- 12.5 Asia - Market size and forecast 2024-2029
- 12.5.1 China - Market size and forecast 2024-2029
- 12.5.2 Japan - Market size and forecast 2024-2029
- 12.5.3 India - Market size and forecast 2024-2029
- 12.5.4 South Korea - Market size and forecast 2024-2029
- 12.5.5 Indonesia - Market size and forecast 2024-2029
- 12.5.6 Thailand - Market size and forecast 2024-2029
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- 12.6.1 Brazil - Market size and forecast 2024-2029
- 12.6.2 Saudi Arabia - Market size and forecast 2024-2029
- 12.6.3 Argentina - Market size and forecast 2024-2029
- 12.6.4 Colombia - Market size and forecast 2024-2029
- 12.6.5 UAE - Market size and forecast 2024-2029
- 12.6.6 South Africa - Market size and forecast 2024-2029
- 12.6.7 Turkey - Market size and forecast 2024-2029
- 12.6.8 Israel - Market size and forecast 2024-2029
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rising global prevalence of infertility and expanding utilization of ART
- Technological advancements and product innovation in biopharmaceutical production
- Expanding therapeutic applications and growing off-label usage
- 13.2 Market challenges
- Regulatory hurdles and biosimilar conundrum
- Intensifying threat of product diversion and illicit use
- Supply chain vulnerabilities and raw material sourcing constraints
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities
- Emerging trend of delayed pregnancies among women coupled with expanding ART centers
- Strategic product approvals and intensifying pharmaceutical sector engagement
- Growing disposable income and healthcare expenditure in emerging economies
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Abbott Laboratories
- Abbott Laboratories - Overview
- Abbott Laboratories - Business segments
- Abbott Laboratories - Key news
- Abbott Laboratories - Key offerings
- Abbott Laboratories - Segment focus
- SWOT
- 15.5 Cipla Inc.
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key news
- Cipla Inc. - Key offerings
- Cipla Inc. - Segment focus
- SWOT
- 15.6 Corona Remedies Pvt. Ltd.
- Corona Remedies Pvt. Ltd. - Overview
- Corona Remedies Pvt. Ltd. - Product / Service
- Corona Remedies Pvt. Ltd. - Key offerings
- SWOT
- 15.7 Emcure Pharmaceuticals Ltd.
- Emcure Pharmaceuticals Ltd. - Overview
- Emcure Pharmaceuticals Ltd. - Product / Service
- Emcure Pharmaceuticals Ltd. - Key offerings
- SWOT
- 15.8 Ferring BV
- Ferring BV - Overview
- Ferring BV - Product / Service
- Ferring BV - Key news
- Ferring BV - Key offerings
- SWOT
- 15.9 Fresenius Kabi AG
- Fresenius Kabi AG - Overview
- Fresenius Kabi AG - Product / Service
- Fresenius Kabi AG - Key offerings
- SWOT
- 15.10 Glenmark Pharmaceuticals Ltd.
- Glenmark Pharmaceuticals Ltd. - Overview
- Glenmark Pharmaceuticals Ltd. - Product / Service
- Glenmark Pharmaceuticals Ltd. - Key offerings
- SWOT
- 15.11 Intas Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd. - Overview
- Intas Pharmaceuticals Ltd. - Product / Service
- Intas Pharmaceuticals Ltd. - Key offerings
- SWOT
- 15.12 Lee BioSolutions Inc
- Lee BioSolutions Inc - Overview
- Lee BioSolutions Inc - Product / Service
- Lee BioSolutions Inc - Key offerings
- SWOT
- 15.13 Lijun Pharmaceutical Group Co., Ltd.
- Lijun Pharmaceutical Group Co., Ltd. - Overview
- Lijun Pharmaceutical Group Co., Ltd. - Product / Service
- Lijun Pharmaceutical Group Co., Ltd. - Key offerings
- SWOT
- 15.14 Lupin Ltd.
- Lupin Ltd. - Overview
- Lupin Ltd. - Business segments
- Lupin Ltd. - Key news
- Lupin Ltd. - Key offerings
- Lupin Ltd. - Segment focus
- SWOT
- 15.15 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.16 Ningbo Renjian Pharmaceutical Group Co., Ltd
- Ningbo Renjian Pharmaceutical Group Co., Ltd - Overview
- Ningbo Renjian Pharmaceutical Group Co., Ltd - Product / Service
- Ningbo Renjian Pharmaceutical Group Co., Ltd - Key offerings
- SWOT
- 15.17 Organon and Co.
- Organon and Co. - Overview
- Organon and Co. - Product / Service
- Organon and Co. - Key offerings
- SWOT
- 15.18 Sanzyme Pvt. Ltd.
- Sanzyme Pvt. Ltd. - Overview
- Sanzyme Pvt. Ltd. - Product / Service
- Sanzyme Pvt. Ltd. - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
